Quinoline: A promising antitubercular target

Dec 3, 2014Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Quinoline as a promising target for tuberculosis treatment

AI simplified

Abstract

Quinoline compounds may offer new therapeutic targets for tuberculosis treatment.

  • Tuberculosis is a chronic disease caused by various strains of Mycobacterium tuberculosis.
  • Current treatment for TB relies on long-duration, multidrug regimens that have not changed significantly in the last 50 years.
  • Resistance to conventional antibiotics has created a need for new therapeutic strategies against M. tuberculosis.
  • Quinoline compounds are recognized for their medicinal chemistry applications and have demonstrated effective anti-TB activity.
  • The synthetic versatility of quinoline allows for the creation of numerous structurally diverse derivatives that may enhance treatment options.
  • This review compiles existing research to highlight the potential of quinoline-based compounds in developing more effective and less toxic anti-TB drugs.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free